Cart
sales@molnova.com
PI3K-IN-16
CAS No. 1895876-81-9
PI3K-IN-16 ( —— )
Catalog No. M12977 CAS No. 1895876-81-9
PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePI3K-IN-16
-
NoteResearch use only, not for human use.
-
Brief DescriptionPI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor.
-
DescriptionPI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor with cell IC50 of 12 nM (in PTEN null MDA-MB-468 cell) and 47 nM (in Jeko-1 B-cell), respectively; exhibits no significant activity on PI3Kα; shows profound pharmacodynamic modulation of AKT phosphorylation, excellent tumour growth inhibition in a mouse PTEN-deficient PC3 prostate tumour xenograft.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1895876-81-9
-
Formula Weight467.50
-
Molecular FormulaC25H26FN3O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name8-((8-fluoro-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)methyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Barlaam B, et al. Bioorg Med Chem Lett. 2016 May 1;26(9):2318-23.
molnova catalog
related products
-
GNE-317
GNE-317 (GNE317) is a potent, brain penepenetrant, dual PI3K/mTOR inhibitor having physicochemical properties predictive of low efflux by P-gp and BCRP.
-
GNE-490
GNE-490 is a potent, selective, orally available class I PI3K inhibitor.
-
MOMIPP
MOMIPP is a PIKfyve inhibitor and a macropinocytosis inducer. MOMIPP readily penetrates the blood-brain barrier and is moderately effective in suppressing progression of intracerebral glioblastoma xenografts.
